Sonoma Bio bets on ‘professional’ Tregs and in-house manufacturing with $265M series B

Sonoma Bio has planted a flag for therapies based on the isolation and expansion of a rare “professional” Treg subset, and plans to own the manufacturing process by building out its own facility.

The company’s two lead programs, a CAR regulatory T cell (Treg) therapy for rheumatoid arthritis (RA) and an effector T cell-clearing conditioning treatment, are slated to enter the clinic around 2H22 and YE21, respectively...